TIMP-GLIA in Well-controlled Celiac Disease Undergoing Oral Gluten Challenge
Celiac Disease
Enrolment: 34 · Results not recorded
Loading the evidence…
Drug · No ChEMBL entity: this is an unloaded polymeric particle, not a defined chemical entity. FLAGGED: the 3 retained trials are TIMP-GLIA/TAK-101 (Takeda, originally Cour Pharmaceuticals CNP-101), which are 500 nm PLGA nanoparticles ENCAPSULATING gliadin antigen. The shard entry specifies a particle NOT conjugated to any drug, i.e. the cargo-free tolerogenic particle. Same platform and same particle chemistry, different product configuration, so this is platform-level rather than agent-level translation evidence and needs manual review.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Celiac Disease
Enrolment: 34 · Results not recorded
Celiac Disease
Enrolment: 102 · Results not recorded
Celiac Disease
Enrolment: 23 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Two experimental traumatic brain injury models: controlled cortical impact (3 mm craniotomy, 2 mm impactor tip, 2 mm cortical deformation at 3.00 m/s with 30 second dwell, targeting visual or sensorimotor cortex) and moderate weight-drop closed head injury (240 g weight dropped 1.4 m onto the anaesthetised mouse resting on prescored foil)
In controlled cortical impact, nanoparticle treatment cut total cells in the lesion area by 44.0%, infiltrating macrophages/monocytes by 84.5%, overall myeloid cells by 65.8% and Ly6C inflammatory monocytes by 72.4% at 72 hours, and reduced lesion volume by 44.7% at 10 weeks with a less intense per…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.